Acute Coronary Syndrome’s Pathophysiology: From Plaque to Infarction

Acute coronary syndrome kills by stopping blood flow to the heart muscle at the exact moment when that muscle needs oxygen most. The condition does not appear suddenly without warning but results from years of silent damage to the coronary arteries, damage that can become lethal in seconds once a critical threshold is crossed. Understanding how acute coronary syndrome develops requires tracing the process from the first fatty deposits in artery walls through the catastrophic rupture of unstable plaques that triggers complete vessel blockage.

The pathophysiology reveals why some patients experience crushing chest pain while others feel only mild discomfort, why certain plaques remain stable for decades while others rupture without provocation, and why treatments must address not just the blocked artery but the entire inflammatory process driving the disease. This article examines the biological mechanisms behind acute coronary syndrome, from the initial endothelial injury through the formation of occlusive thrombus, explaining how each stage increases the risk of myocardial infarction and sudden cardiac death.

Acute coronary syndrome encompasses three related conditions that share a common pathophysiological origin: unstable angina, non-ST-elevation myocardial infarction, and ST-elevation myocardial infarction. All three result from reduced blood flow through coronary arteries, but they differ in severity and duration of ischemia. The coronary arteries supply oxygen-rich blood to the myocardium, and any interruption in this supply creates an imbalance between oxygen demand and oxygen delivery. When this imbalance persists beyond the heart's tolerance, myocardial cells begin to die, releasing biomarkers like troponin that confirm tissue damage. The syndrome typically begins with atherosclerosis, the gradual accumulation of lipids, inflammatory cells, and fibrous tissue within the arterial wall. Over time, these deposits form plaques that narrow the vessel lumen and alter normal blood flow. The acute phase occurs when a vulnerable plaque ruptures or erodes, exposing thrombogenic material to circulating blood and triggering rapid clot formation that partially or completely obstructs the artery. This transformation from chronic stable disease to acute life-threatening emergency defines the pathophysiology of acute coronary syndrome.

The pathophysiological cascade begins with endothelial dysfunction, often years before any symptoms appear. The endothelium, the single-cell layer lining blood vessels, normally prevents lipid infiltration and maintains an antithrombotic surface. Risk factors including hypertension, diabetes, smoking, and elevated cholesterol damage this protective barrier, making it permeable to low-density lipoprotein particles. Once trapped in the arterial wall, these lipoproteins undergo oxidation, triggering an inflammatory response that recruits monocytes and T-lymphocytes to the site. The monocytes transform into macrophages that engulf oxidized lipids, becoming foam cells that accumulate in the vessel wall. This collection of foam cells, smooth muscle cells, and extracellular lipid forms the fatty streak, the earliest visible sign of atherosclerosis. As the lesion grows, smooth muscle cells migrate from the arterial media to the intima, where they proliferate and produce collagen that creates a fibrous cap over the lipid core. The stability of this cap determines whether the plaque remains quiescent or becomes vulnerable to rupture. Plaques with thin fibrous caps and large lipid cores, maintained by ongoing inflammation, represent the highest risk for acute events because mechanical stress or inflammatory enzymes can easily breach the cap.

Plaque rupture or erosion exposes the lipid core and subendothelial collagen to circulating blood, initiating thrombosis through multiple pathways. Tissue factor, abundant in the lipid core, activates the extrinsic coagulation cascade, rapidly generating thrombin that converts fibrinogen to fibrin. Simultaneously, exposed collagen activates platelets through receptors including glycoprotein VI and integrin alpha-2-beta-1, causing platelets to adhere to the injury site. Activated platelets release adenosine diphosphate and thromboxane A2, recruiting additional platelets and amplifying the thrombotic response. The growing thrombus can remain mural, attached to the vessel wall while preserving some blood flow, or it can become occlusive, completely blocking the artery. The extent of thrombosis depends on the size of the plaque rupture, the thrombogenicity of the exposed material, and the balance between prothrombotic and antithrombotic factors in the blood. Occlusive thrombus typically produces ST-elevation myocardial infarction, where transmural ischemia causes characteristic electrocardiographic changes. Non-occlusive thrombus may cause non-ST-elevation myocardial infarction or unstable angina, where ischemia remains subendocardial or intermittent. Thrombus composition also varies, with platelet-rich white thrombus forming under high shear conditions in severely stenotic arteries and fibrin-rich red thrombus developing in slower flow conditions.

The downstream consequences of coronary occlusion depend on the duration and completeness of blood flow interruption. Myocardial cells can tolerate brief periods of ischemia through anaerobic metabolism, but this pathway produces only two ATP molecules per glucose molecule compared to thirty-six through aerobic metabolism. Within minutes of severe ischemia, ATP depletion impairs sodium-potassium pumps, leading to cellular swelling and calcium accumulation that disrupts contractile function. If perfusion is not restored within twenty to thirty minutes, irreversible injury begins in the subendocardium, the layer most vulnerable to ischemia because it experiences the highest wall stress and receives blood last in the coronary perfusion sequence. Necrosis then progresses outward toward the epicardium in a wavefront pattern, with the final infarct size determined by the duration of occlusion and the presence of collateral blood flow. Reperfusion, while essential for salvaging viable myocardium, paradoxically causes additional injury through oxygen free radical formation, calcium overload, and inflammatory cell infiltration. Dead myocytes release intracellular contents including troponin and creatine kinase-MB, biomarkers that confirm infarction and guide treatment decisions. The infarcted region becomes permanently scarred, reducing cardiac function and increasing the risk of heart failure and arrhythmias.

Beyond the mechanical obstruction, acute coronary syndrome involves systemic inflammation and prothrombotic state changes that extend risk beyond the culprit lesion. Inflammatory markers including C-reactive protein and interleukin-6 rise during acute events, reflecting both local plaque inflammation and systemic activation of immune responses. This inflammatory surge destabilizes other vulnerable plaques throughout the coronary tree, explaining why patients often have multiple high-risk lesions and why recurrent events frequently occur in different arterial territories. Platelet activation persists even after initial treatment, and hypercoagulability continues for weeks or months, necessitating prolonged antithrombotic therapy. Microvascular dysfunction develops in some patients, where microscopic vessels become obstructed by microemboli or undergo vasospasm, preventing effective tissue perfusion despite successful opening of the main artery. The interplay between these mechanisms explains the variability in patient outcomes and the necessity of addressing acute coronary syndrome as a systemic disease rather than an isolated plaque problem. Recognition of these broader pathophysiological processes has led to comprehensive treatment strategies targeting inflammation, thrombosis, and myocardial protection simultaneously.

The pathophysiology of acute coronary syndrome represents a continuum from initial endothelial injury through atherosclerotic plaque formation to the catastrophic rupture that triggers acute ischemia and myocardial necrosis. Each stage involves complex interactions between lipids, inflammatory cells, coagulation factors, and vascular responses that determine whether the disease remains stable or progresses to life-threatening occlusion. The mechanisms explain clinical patterns, from the sudden onset of symptoms to the variable presentations ranging from mild discomfort to cardiogenic shock. Modern treatments target specific steps in this pathophysiological sequence, using antiplatelet agents to prevent thrombosis, statins to stabilize plaques, and reperfusion strategies to salvage ischemic myocardium. Understanding these underlying processes remains essential for clinicians managing acute coronary syndrome and for researchers developing new interventions to prevent the progression from chronic atherosclerosis to acute cardiac events that continue to cause significant mortality worldwide.

Did you like this example?

231

10